Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel

• Published in: Journal of the American College of Cardiology Vol. 67; no. 8; pp. 936 - 947
• Main Authors: Doll, Jacob A., Neely, Megan L., Roe, Matthew T., Armstrong, Paul W., White, Harvey D., Prabhakaran, Dorairaj, Winters, Kenneth J., Duvvuru, Suman, Sundseth, Scott S., Jakubowski, Joseph A., Gurbel, Paul A., Bhatt, Deepak L., Ohman, E. Magnus, Fox, Keith A.A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2016; Elsevier Limited
• Subjects: acute coronary syndrome; Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - genetics; Acute coronary syndromes; Aged; Alleles; Angina pectoris; Blood platelets; Cardiology; Cardiovascular; Cardiovascular disease; Clinical outcomes; Confidence intervals; Coronary vessels; Cytochrome P-450 CYP2C19 - genetics; Cytochrome P-450 CYP2C19 - metabolism; Deoxyribonucleic acid; DNA; DNA - genetics; Dose-Response Relationship, Drug; Double-Blind Method; Drug dosages; dual antiplatelet therapy; Enzymes; Female; Follow-Up Studies; Genetics; Genotype; Genotype & phenotype; Heart attacks; Humans; Male; Metabolism; Metabolites; Middle Aged; Platelet Aggregation Inhibitors - administration & dosage; Platelet Function Tests; platelets; Polymorphism, Genetic; Prasugrel Hydrochloride - administration & dosage; Purinergic P2Y Receptor Antagonists - administration & dosage; Retrospective Studies; Stroke; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Treatment Outcome; United States > US; California; NSTEMI; FDA; CI; EM; HR; UA; platelets; dual antiplatelet therapy; ACS; PRU; acute coronary syndrome; genetics; PCI; CYP; RM; MI; myocardial infarction; P2Y 12 reaction unit; percutaneous coronary intervention; extensive metabolizer(s); non–ST-segment elevation myocardial infarction; U.S. Food and Drug Administration; cytochrome P450; reduced metabolizer(s); hazard ratio; confidence interval; unstable angina
• ISSN: 0735-1097; 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2015.12.036

Certain alleles of the CYP2C19 gene are associated with higher platelet reactivity and increased ischemic events among patients treated with clopidogrel. However, the relationship of CYP2C19 genotype and outcomes in medically managed patients with acute coronary syndromes (ACS) is not known. This study sought to assess the effect of CYP2C19 genotype on ischemic outcomes in patients with ACS initially managed medically without revascularization who were randomized to either clopidogrel or prasugrel. We classified patients as extensive metabolizers (EM) or reduced metabolizers (RM) based on CYP2C19 genotype and evaluated ischemic outcomes and platelet reactivity. Among 9,326 patients enrolled from 2008 to 2011, 5,736 participated in the genetics cohort; of these, 2,236 had platelet function testing data. There was no association between CYP2C19 metabolizer status (EM vs. RM) and the primary composite endpoint of cardiovascular death, myocardial infarction (MI), or stroke (hazard ratio [HR]: 0.86). EM and RM patients had similar rates of the primary endpoint whether treated with prasugrel (HR: 0.82) or clopidogrel (HR: 0.91; p for interaction = 0.495). After adjusting for clinical and treatment variables, EM patients had a lower risk of MI versus RM patients (HR: 0.80), but risks of other outcomes were similar. RM patients had significantly higher mean P2Y12 reaction units versus EM patients when treated with clopidogrel (39.93), but not with prasugrel (3.87). CYP2C19 metabolizer status is not associated with the composite outcome of cardiovascular death, MI, or stroke in medically managed ACS patients treated with clopidogrel or prasugrel. Our findings do not support routine CYP2C19 genetic testing in this population. (A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects [TRILOGY ACS]; NCT00699998)